# Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

Study · id `cardio:ct-nct03198793` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03198793](<https://clinicaltrials.gov/study/NCT03198793>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03198793

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

## Technical summary

Registry record NCT03198793. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2018-10-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT03198793, source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)
- Started: 2017-10-13 (actual) (ClinicalTrials.gov record NCT03198793, source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)
- Primary completion: 2018-10-16 (actual) (ClinicalTrials.gov record NCT03198793, source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)
- Completion: 2018-11-12 (actual) (ClinicalTrials.gov record NCT03198793, source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03198793, source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03198793-2018-12-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
- Acronym: NEW-HOPE
- Condition: Hypertension
- Intervention (Drug): QGC001
- Lead sponsor: Quantum Genomics SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Quantum Genomics SA (`cardio:org-quantum-genomics-sa`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins (`cardio:pubmed-31014072`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cf7e111752c5ddc068c67f892e946afe670ee80b714e37e70336c1802d9bd7ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
